Following a recent twin signing with Key Opinion Leaders (KOLs) in the Middle East and Europe, Memphasys has lined up another two international partners to take part in in-vitro assessments of its revolutionary bio-separations technology.
Internationally renowned fertility and andrology outfits are increasingly looking to take part in the trials, with Memphasys’s Felix device showing promise for separating high-quality spermatozoa to increase the likelihood of successful IVF treatment.
The latest KOLs have been signed with Boston IVF in the USA and the Centre of Reproductive Medicine and Andrology (CeRA), located at the University of Münsterin Germany.
Boston IVF operates runs one of the largest IVF centres in the USA and has facilities in five other US states.
The group is also affiliated with The Beth Israel Deaconess Medical Center and Harvard University’s School of Medicine.
The Boston IVF team will be led by Dr. Denny Sakkas, Associate Professor at the Department of Obstetrics, Gynecology and Reproductive Sciences at the Yale University School of Medicine. Dr Sakkas is also the Scientific Director at Boston IVF.
CeRA is a well-respected research facility and clinical service provider in andrology and reproduction.
The organisation hosts its own Institute of Reproductive and Regenerative Biology, a Department of Clinical Andrology and an Assisted Reproduction Unit.
The CeRA team will be led by Professor Schlatt, a well published international leader in reproductive medicine.
Commenting on the two additional KOLs, Memphasys executive chairman, Ms Alison Coutts, said:
We are delighted that two more major centres led by such world-renowned fertility experts have agreed to be involved in clinical validation of the Felix device as part of its commercialisation process.
“The recruitment of the current seven reference centres represents major IVF markets in the United States, Europe and the Middle East and more will be announced shortly,” she said.
Memphasys is aiming to sign between 10 and 15 KOLs to participate in its trials.
The addition of Boston IVF and CeRA takes its total to seven partners.
